RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
RBC Capital analyst Brian Abrahams upgrades Lakefront Biotherapeutics (NASDAQ:LKFT) from Sector Perform to Outperform and raises the price target from $26 to $45.
RBC Capital analyst Brian Abrahams upgrades Lakefront Biotherapeutics (NASDAQ:LKFT) from Sector Perform to Outperform and raises the price target from $26 to $45.